← All trials
NCT03373214
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2018
- Primary completion
- Feb 28, 2019
- Completion date
- May 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversityReponsible party - principal investigator
- Leiden UniversityCollaborator
- George Washington UniversityCollaborator
- University of AmsterdamCollaborator
- Centre de Recherche Médicale de LambarénéCollaborator
- Centre de Recherche Médicale de LambarénéOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.